Ignite Creation Date:
2024-05-05 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00442351
Status:
TERMINATED
Last Update Posted:
2022-02-09
First Post:
2007-02-28
Brief Title:
Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in MildModerate Persistent Asthmatics Study P04654TERMINATED
Sponsor:
Organon and Co
Organization:
Organon and Co
Study Overview
Official Title:
A Comparative Study of The Efficacy and Tolerability of Maintenance Treatment of Patients With MildModerate Persistent Asthma With Asmanex Twisthaler 220 mcg QD PM Versus Asmanex Placebo QD PM
Status:
TERMINATED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Slow Enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized multicenter placebo-controlled double-blind parallel-group study evaluating Asmanex Twisthaler 220 mcg once daily QD in the evening PM compared with Asmanex Placebo QD PM for 12 weeks Efficacy will be measured for the changes in forced expiratory volume in 1 second FEV1 from baseline to the end of treatment period Week 12 or end of the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| IND Number 46216 SCH 032088 | REGISTRY | NCT00442351 | None |